You can buy or sell AVROBIO and other stocks, options, ETFs, and crypto commission-free!
AVROBIO, Inc. Common Stock, also called AVROBIO, is a clinical stage company that engages in the development of disruptive therapies. Read More It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. The company was founded by Jeffrey Medin and Christopher Paige in 2015 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Avrobio
AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical tria...
-$0.57 per share
Expected Mar 21, Pre-Market